PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31405071-5	2019	EGCG prevented "Cadherin switch" and decreased the expression level of TCF8/ZEB1, beta-Catenin, and Vimentin.	epigallocatechin gallate	0-4	zinc finger E-box binding homeobox 1	Homo sapiens	71-75	
31405071-5	2019	EGCG prevented "Cadherin switch" and decreased the expression level of TCF8/ZEB1, beta-Catenin, and Vimentin.	epigallocatechin gallate	0-4	zinc finger E-box binding homeobox 1	Homo sapiens	76-80	
22971992-13	2013	EGCG inhibited epithelial-mesenchymal transition by upregulating the expression of E-cadherin and inhibiting the expression of N-cadherin and Zeb1.	epigallocatechin gallate	0-4	zinc finger E-box binding homeobox 1	Homo sapiens	142-146	
22957988-9	2012	EGCG decreased the phosphorylation of Smad2 and Erk1/2, inhibited the nuclear translocation of Smad2, and repressed the expression of transcription factors ZEB1, Snail, Slug, and Twist, and up-regulated the expression of E-cadherin.	epigallocatechin gallate	0-4	zinc finger E-box binding homeobox 1	Homo sapiens	156-160	
21796625-7	2012	Furthermore, EGCG inhibited EMT by inhibiting the expression of Snail, Slug and ZEB1, and TCF/LEF transcriptional activity, which correlated with significantly reduced CSC"s migration and invasion, suggesting the blockade of signaling involved in early metastasis.	epigallocatechin gallate	13-17	zinc finger E-box binding homeobox 1	Homo sapiens	80-84	
25759589-4	2015	Treatment with EGCG activates the expression of the BAD, BAK, FAS, IGF1R, WNT11, and ZEB1 genes and inhibits CASP8, MYC, and TP53.	epigallocatechin gallate	15-19	zinc finger E-box binding homeobox 1	Homo sapiens	85-89